Sacral Chordoma: The Loma Linda University Radiation Medicine Experience. Kevin Yiee MD, MPH Resident Physician
|
|
- Shon Terry
- 6 years ago
- Views:
Transcription
1 Sacral Chordoma: The Loma Linda University Radiation Medicine Experience Kevin Yiee MD, MPH Resident Physician
2
3 What is a chordoma? 1 st chordoma discovered in clivus by Virchow and Luschka 1856 Rare tumor arising from notochordal remnants or ectopic notochordal tissue
4 Rudolph Virchow Father of Chordomas
5 Metastasis Chordomas are not benign, can have metastatic potential Lungs, liver, bone most common Other studies report a distant metastasis rate of 5-40% in patients with long term follow up Survival time after metastasis was only 2.4 months
6 Epidemiology Incidence 0.08 per 100,000 people Rare reports of familial chordoma Few extensive case series In past, grouped with other bone neoplasms rather than studied separately
7 Largest population based study for chordomas by McMaster, et al. examining SEER data 400 cases from
8 32% cranial, 33% spine, 29% sacrum, 8% other Male: Female 1.8:1 Males more likely to have sacral presentation, females with cranial presentation Median age at diagnosis 58.5 years (range 3-95)
9 Site of presentation varies with age and gender Youngest more likely to have cranial presentation Oldest patients, sacral tumors more common Median age of sacral presentation is 69
10 Sacral lesions (32%) were more likely than cranial lesions(11%) to be treated with radiotherapy alone 5 year survival for sacral presentation 73.6% 10 year survival 32.2%
11 Clinical Presentation Symptoms can be vague May grow to large size before seeking workup Local pain in almost all Neurological deficits including bladder, bowel symptoms, radiculopathies
12 Imaging Findings Often 1 st detected by CT scanning CT: partially calcified soft tissue mass eroding adjacent bone
13
14
15 Treatment Options Surgery Radiation Surgery + Radiation Chemotherapy
16 Surgery Surgery is treatment of choice when possible Complete excision may lead to neurogenic dysfunction, pelvic instability Resection approach may be posterior or combined anteroposterior
17 Want margins around tumor, optimally 1-2 cm margin of normal bone In large lesions, complete surgical excision usually impossible.
18 Mayo Clinic Mayo Clinic series of sacrococcygeal chordomas between 1980 to new presentation patients in the study Of these, only 40% were able to resected with wide margin
19 Mayo Clinic Results 5 yr overall survival 74% 44% had local recurrence Most important predictor of survival was wide margin
20 Other studies report local control rate of 60-80% with total excision 25-50% with subtotal resection
21 York MD Anderson retrospective series Retrospective study of 27 patients with sacral chordomas at MD Anderson from With radical resection disease free interval was 2.2 years vs only 8 months with subtotal resection
22 Some patients received post-operative radiation after subtotal and gross total resections An improvement in time to recurrence was seen among those receiving post operative XRT
23
24 Radiation Options Photons Charged Particles: Protons, helium, carbon ion
25 Catton et al. study Princess Margaret (photon) Retrospective study of 48 patients with chordoma, including 23 sacral chordoma patients 13 sacral patients received XRT, most receiving 50 Gy in 25 fx Median survival after diagnosis was 62 months No survival advantages for patients receiving >50 Gy vs <50 Gy
26 Schoenthaler et al. study Lawrence Berkeley Laboratory 14 patients with sacral chordoma treated with charged particles helium and neon between Median dose 75.7 CGE given at GyE daily Median follow up 5 years All patients received surgery (2 bx, 4 GTR, 8 STR)
27 All received helium beam, 5 also received photons, 4 also received neon Target: entire sacrum and any evident soft tissue abnormality with 3cm margin to 50 GyE Cone down of gross tumor with 1-2 cm margin received 75.7 GyE
28 Anterior rectum<50 GyE
29 Results of Schoenthaler Study 5 year survival 85% 5 year local control 55% 7 recurrences, with 2 of these patients recurring outside of radiation field
30 Of the 4 patients who had total resection, 3 remain free of disease Of the 10 patients who had partial excision or biopsy, only 3 remain free of disease
31 Hug study(protons) patients at Massachusetts General Hospital and Harvard Cyclotron Laboratory treated for chordomas, chondrosacromas, osteogenic sarcomas, giant cell tumors, osteo or chondroblastomas Included 14 spinal and sacral chordoma patients (8 sacral) Of spinal/sacral chordoma patients, mean dose given was 74.6 CGE
32 10 patients received pre and postop XRT to mean dose of 75.2 CGE Mean follow up time 3.2 years
33 5/14 patients (36%) failed locally 4 within the radiation field, 1 outside 1/4 patients (25%) with gross total resection failed locally 3/8 patients (38%) with subtotal resection failed locally
34 Trend toward local control for target doses>77 CGE but not statistically sig 5 year local recurrence free survival rate 53% 5 year overall survival rate 50%
35
36
37 Study Design Retrospective review of 22 patients treated at LLUMC for sacral chordomas between patients excluded from analysis due to metasatic disease at presentation 6 records unavailable for followup
38 Endpoints to be examined included overall survival, disease free survival, local control All patients had a surgical procedure: 1 biopsy only, 7 subtotal resection, 11 gross total resection
39 Radiation dose ranged from 66.6 CGE to 81 CGE Average dose 73.6 CGE 8 patients had combination therapy of proton and photon beams GTV: preoperative tumor volume CTV: Add 0.5 cm around GTV Limit rectal dose to 50.4 CGE
40 70 yo male presenting with 15 yr history of coccygeal pain
41
42
43
44 52 yo male with recuurent sacral chordoma, s/p 3 subtotal resections
45
46
47 Patient Description 4 females, 15 males Age range: Average age: 60.8
48 Distant Mets On initial presentation 2 patients had distant metastases Areas include lung, liver
49 Overall Survival 5 yr OS 80%
50 Disease Free Survival 5 yr DFS 60%
51 Median time before recurrence 64 months (95% CI of 43 to 85 months)
52 Local Control 5 yr LC 60%
53 Distant Control 5 yr DC 75%
54 Analyzed by extent of surgery: total resection vs subtotal resection
55 Overall Survival by Surgery Type 5 yr OS: Total resection 89% Subtotal resection 73% p=0.60
56 Median time to recurrence 86 months for patients with total resection Median time to recurrence 44 months for patients with subtotal resection
57 Local Control by Surgery Type 5 yr LC: Total resection 90% Subtotal resection 29% p=.02
58 Distant Control by Surgery Type 5 yr DC: Total resection 100% Subtotal 40% p=0.84
59 Patients analyzed by status at study entry Before Failure group: Patients treated after initial diagnosis without recurrence After Failure group: Patients treated after recurrence
60 Overall Survival by Study Entry 5 yr OS: Before Failure 100% After Failure: 61% p=0.11
61 Local Control by Study Entry 5 yr LC: Before Failure 70% After Failure 52% p=0.70
62 Distant Control by Study Entry 5 yr distant control: Before Failure 80% After Failure 71% p=0.29
63
64 Symptomatic Relief 15 patients had pain on presentation 11 had improvement in pain 4 did not have pain relief and/or worsened
65 Motor Symptoms 7 had motor difficulty at presentation Of these 5 had improvement
66 Late Morbidity
67 Late Morbidity Skin morbidity: No patients developed Grade 3 or higher late morbidity 5 patients had Grade 1, 2 scores Subcutaneous morbidity: 1 patient had grade 3 3 patients had Grade 1, 2 scores Only other late morbidity was one patient who developed Grade 3 bone complication
68 Summary 5 yr overall survival 80% 5 yr disease free survival 60% 5 yr local control 60% 5 yr distant control 75%
69 Conclusions Surgery is important factor for local control (significant difference) In our study patients with total resection had a 5 year local control rate of 90%, subtotal resection 29% However, total resection often not possible
70 Future Followup Dose escalation possibilities Appears most failures are within radiation field in past studies Investigate rectal toxicity Increase dose to rectum, bladder to determine if dose escalation possible for increased tumor control
71
Carbon Ion Radiotherapy for Skull Base and Paracervical Chordomas
Carbon Ion Radiotherapy for Skull Base and Paracervical Chordomas Azusa Hasegawa, Jun-etsu Mizoe and Hirohiko Tsujii Research Center Hospital for Charged Particle Therapy National Institute of Radiological
Proton-Radiotherapy for Tumors of the Skull Base: Indications, Advantages, Limitations
Proton-Radiotherapy for Tumors of the Skull Base: Indications, Advantages, Limitations Eugen B. Hug, MD Director, Center for Proton-Radiotherapy, Paul Scherrer Institut, Villigen and Chair of Proton-Radiotherapy.
Proton Radiation Therapy for Osteosarcomas, Chondrogenic Tumors and Soft Tissue Sarcomas
Proton Radiation Therapy for Osteosarcomas, Chondrogenic Tumors and Soft Tissue Sarcomas Eugen B. Hug Center for Proton Radiation Therapy Paul Scherrer Institute Is there a place for Proton/Particle Radiotherapy
Status of H 1 and C 12
Status of H 1 and C 12 Herman Suit No Conflict of Interest 1 Goal of a New Treatment Modality Tumor Control Probability or No in Complication Rate 2 Truism No Advantage to: any Patient for any Radiation
Proton Radiation Therapy for Osteosarcomas, Chondrogenic Tumors and Soft Tissue Sarcomas
Proton Radiation Therapy for Osteosarcomas, Chondrogenic Tumors and Soft Tissue Sarcomas Eugen B. Hug Center for Proton Radiation Therapy Paul Scherrer Institute Histologies Osteogenic Tumors Osteogenic
Proton Radiotherapy for Skull Base and Para-spinal Tumors
Proton Radiotherapy for Skull Base and Para-spinal Tumors Carmen Ares Primary tumors Tumors of the Skull Base - Chordomas, Chondrosarcomas Secondary infiltration or involvement by intracranial tumors -
Radiation Therapy for Soft Tissue Sarcomas
Radiation Therapy for Soft Tissue Sarcomas Alexander R. Gottschalk, MD, PhD Assistant Professor, Radiation Oncology University of California, San Francisco 1/25/08 NCI: limb salvage vs. amputation 43 patients
Case Conference: SBRT for spinal metastases D A N I E L S I M P S O N M D 3 / 2 7 / 1 2
Case Conference: SBRT for spinal metastases D A N I E L S I M P S O N M D 3 / 2 7 / 1 2 Case 79 yo M with hx of T3N0 colon cancer diagnosed in 2008 metastatic liver disease s/p liver segmentectomy 2009
Clinical Results of Carbon Ion Radiotherapy: The Heidelberg Experience
Clinical Results of Carbon Ion Radiotherapy: The Heidelberg Experience Stephanie E. Combs, MD Department of Radiation Oncology University of Heidelberg, Germany Carbon ion RT at GSI Active beam delivery
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX Site Group: Gynecology Cervix Author: Dr. Stephane Laframboise 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING AND
Particle Therapy for Tumors of the Skull Base. Eugen B. Hug, MD Medical Director, ProCure Proton Therapy Centers, NY
Particle Therapy for Tumors of the Skull Base Eugen B. Hug, MD Medical Director, ProCure Proton Therapy Centers, NY Particle Radiation Therapy for Tumors of the Skull Base Primary skull base tumors: Chordoma,
Outline. WBRT field. Brain Metastases. Whole Brain RT Prophylactic WBRT Stereotactic radiosurgery (SRS) 1 fraction Stereotactic frame
Radiation Therapy for Advanced NSC Lung Ca Alexander Gottschalk, M.D., Ph.D. Associate Professor Director of CyberKnife Radiosurgery Department of Radiation Oncology University of California San Francisco
Proton Therapy for tumors of the skull base - RESULTS. Eugen B. Hug, MD Medical Director, ProCure Proton Therapy Centers, NY
Proton Therapy for tumors of the skull base - RESULTS Eugen B. Hug, MD Medical Director, ProCure Proton Therapy Centers, NY Petroclival Chondrosarcoma: 68 72 Gy(RBE) at 1.8 or 2.0 Gy(RBE) GTV: 70.2 Gy(RBE)
HEAVY PARTICLE THERAPY
HEAVY PARTICLE THERAPY DR. G.V. GIRI KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY ICRO 2012 BHATINDA HEAVY PARTICLES USED IN A EFFORT TO IMPROVE TUMOR CONTROL, THAT DO NOT RESPOND TO PHOTONS OR ELECTRONS BETTER
What s new in bone and soft tissue sarcoma Treatment and Guidelines 2012? Rob Grimer
What s new in bone and soft tissue sarcoma Treatment and Guidelines 2012? Rob Grimer ESMO conference 2012 Top Oncologists in world (~ 400) Lots of sarcoma basic science key messages: 40% of STS diagnoses
INTRAOPERATIVE RADIATION THERAPY FOR RETROPERITONEAL SARCOMA
INTRAOPERATIVE RADIATION THERAPY FOR RETROPERITONEAL SARCOMA ISIORT 2014 Ivy A Petersen, MD Mayo Clinic Rochester, MN NOTHING TO DISCLOSE SOFT TISSUE SARCOMAS 2014 Estimated cases in the USA 12,020 diagnosed
Insights into Thymic Epithelial Tumors: Radiation Therapy
Insights into Thymic Epithelial Tumors: Radiation Therapy Charles R. Thomas, MD Professor and Chairman, Department of Radiation Medicine Professor, Department of Medicine, Division of Hematology/Medical
UCSF Uveal Melanoma Program: Outcomes with Proton Beam Radiation Therapy Kavita K. Mishra, M.D., M.P.H. UCSF Comprehensive Cancer Center
Disclosures UCSF Uveal Melanoma Program: Outcomes with Proton Beam Radiation Therapy No disclosures Kavita K. Mishra, M.D., M.P.H. UCSF Comprehensive Cancer Center UCSF Uveal Melanoma Program: Ocular Melanoma
Chapter 5 Section 3.1
Radiology Chapter 5 Section 3.1 Issue Date: March 27, 1991 Authority: 32 CFR 199.4(b)(2), (b)(2)(x), (c)(2)(viii), and (g)(15) 1.0 CPT 1 PROCEDURE CODES 37243, 61793, 61795, 77261-77421, 77427-77799, 0073T
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM EPENDYMOMA Last Revision Date July 2015 1 CNS Site Group Ependymoma Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2.
Surgical Treatment of Spine Surgery Experience Primary Spinal Neoplasms ( ) Ziya L. Gokaslan, MD, FACS Approximately 3500 spine tumor
Surgical Treatment of Primary Spinal Neoplasms Ziya L. Gokaslan, MD, FACS Donlin M. Long Professor Professor of Neurosurgery, Oncology & Orthopaedic Surgery Vice Chairman Director of Spine Program Department
The use of surgery in the elderly. for management of metastatic epidural spinal cord compression
The use of surgery in the elderly Bone Tumor Simulators for management of metastatic epidural spinal cord compression Justin E. Bird, M.D. Assistant Professor Orthopaedic Oncology and Spine Surgery Epidemiology
Multidisciplinary management of retroperitoneal sarcomas
Multidisciplinary management of retroperitoneal sarcomas Eric K. Nakakura, MD UCSF Department of Surgery UCSF Comprehensive Cancer Center San Francisco, CA 7 th Annual Clinical Cancer Update North Lake
PTCOG 46. Educational Workshop Session IV. Head & Neck CLINICAL. J. Mizoe (NIRS, Japan)
PTCOG 46 Educational Workshop Session IV CLINICAL Head & Neck J. Mizoe (NIRS, Japan) Photon X-Ray γ-ray Fast Neutron Non-Charged Radiation Electron Proton Helium Light Ion Heavy Particle Carbon Neon Argon
Thoracic Recurrences. Soft tissue recurrence
Stereotactic body radiotherapy for thoracic and soft malignancies Alexander Gottschalk, M.D., Ph.D. Associate Professor Director of CyberKnife Radiosurgery Department of Radiation Oncology University of
Protons for Head and Neck Cancer. William M Mendenhall, M.D.
Protons for Head and Neck Cancer William M Mendenhall, M.D. Protons for Head and Neck Cancer Potential Advantages: Reduce late complications via more conformal dose distributions Likely to be the major
8/1/2017. Clinical Indications and Applications of Realtime MRI-Guided Radiotherapy
Clinical Indications and Applications of Realtime MRI-Guided Radiotherapy Michael F Bassetti MD PhD Assistant Professor, Department of Human Oncology University of Wisconsin, Madison. Carbone Cancer Center
Disclosures. Proton therapy advantages. Why are comparing therapies difficult? Proton Therapy for Low Risk Prostate Cancer
Proton Therapy for Low Risk Prostate Cancer Disclosures No relevant financial disclosures This presentation will not discuss off-label or investigational treatments Andrew K. Lee, MD, MPH Associate Professor
Advances in radiation oncology in the management of soft tissue sarcoma 放疗于治疗肉瘤的最新发展
Advances in radiation oncology in the management of soft tissue sarcoma 放疗于治疗肉瘤的最新发展 Brian O Sullivan Bartley-Smith / Wharton Chair Professor, Department of Radiation Oncology The Princess Margaret / University
Preoperative adjuvant radiotherapy
Preoperative adjuvant radiotherapy Dr John Hay Radiation Oncology Program BC Cancer Agency Vancouver Cancer Centre The key question for the surgeon Do you think that this tumour can be resected with clear
Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016. Background
Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016 Background Mostly adenocarcinoma (scc possible, but treated like anal cancer) 39, 220 cases annually Primary treatment: surgery
Proton or Photon RT for Retroperitoneal Sarcomas
Principle Investigator Thomas F. DeLaney, M.D. Contact Additional Info Institution Thomas DeLaney, MD 617-726-6876 tdelaney@partners.org www.clinicaltrials.gov NCT01659203 Massachusetts General Hospital
Radiotherapy for Rectal Cancer. Kevin Palumbo Adelaide Radiotherapy Centre
Radiotherapy for Rectal Cancer Kevin Palumbo Adelaide Radiotherapy Centre Overview CRC are common (3 rd commonest cancer) rectal Ca approx 25-30% of all CRC. Presentation PR bleeding: beware attributing
PEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING
PEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING ANATOMY ANATOMY CONT ANATOMY CONT. ANATOMY CONT. EYE OF A CHILD Normal tissue tolerance doses (in conventional #) TD 5/5 TD 50/5 Endpoint Gy Gy Optic nerve
QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX
QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX MP/H Quiz 1. A patient presented with a prior history of squamous cell carcinoma of the base of the tongue. The malignancy was originally diagnosed
Navigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News
Navigating the Stream: Prostate Cancer and Early Detection Ifeanyi Ani, M.D. TPMG Urology Newport News Understand epidemiology of prostate cancer Discuss PSA screening and PSA controversy Review tools
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM MENINGIOMA CNS Site Group Meningioma Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION 3 2. PREVENTION
Case Conference. Craig Morgenthal Department of Surgery Long Island College Hospital
Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for
Andrew K. Lee, MD, MPH Associate Professor Department tof fradiation Oncology M.D. Anderson Cancer Center
Proton Therapy for Prostate Cancer Andrew K. Lee, MD, MPH Associate Professor Department tof fradiation Oncology M.D. Anderson Cancer Center Seungtaek Choi, MD Assistant Professor Department tof fradiation
Clinical Case Conference
Clinical Case Conference Palliative radiation therapy for bone metastasis Jeff Burkeen, MD, PGY2 7/20/2015 1 Overview Epidemiology Pathophysiology Common presentations and symptoms Imaging Surgery Radiation
QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX
QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX MP/H Quiz 1. A patient presented with a prior history of squamous cell carcinoma of the base of the tongue. The malignancy was originally diagnosed
Where are we with radiotherapy for biliary tract cancers?
Where are we with radiotherapy for biliary tract cancers? Professor Maria A. Hawkins Associate Professor in Clinical Oncology MRC Group Leader/Honorary Consultant Clinical Oncologist CRUK MRC Oxford Institute
Protontherapy in paediatric skull base and cervical canal chordomas. Long term outcome
Protontherapy in paediatric skull base and cervical canal chordomas. Long term outcome Jean-Louis Habrand, MD François Baclesse Cancer Center- Caen University, Institut Curie-Proton Therapy Center (ICPO),
Questions may be submitted anytime during the presentation.
Understanding Radiation Therapy and its Role in Treating Patients with Pancreatic Cancer Presented by Pancreatic Cancer Action Network www.pancan.org August 18, 2014 If you experience technical difficulty
Proton radiation therapy for chordomas and chondrosarcomas of the skull base
J Neurosurg 91:432 439, 1999 Proton radiation therapy for chordomas and chondrosarcomas of the skull base EUGEN B. HUG, M.D., LILIA N. LOREDO, M.D., JERRY D. SLATER, M.D., ALEXANDER DEVRIES, M.D., ROGER
PRIMARY STUDIES EN BLOC VERSUS DEBULKING
PRIMARY STUDIES EN BLOC VERSUS DEBULKING I Study ID II Method III Patient characteristics IV Intervention(s) V Results primary outcome VI Results secondary and other outcome(s) VII Critical appraisal of
Index. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM BRAIN METASTASES CNS Site Group Brain Metastases Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
When to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
ES-SCLC Joint Case Conference. Anthony Paravati Adam Yock
ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar
Disclosures. Overview 8/3/2016. SRS: Cranial and Spine
SRS: Cranial and Spine Brian Winey, Ph.D. Department of Radiation Oncology Massachusetts General Hospital Harvard Medical School Disclosures Travel and research funds from Elekta Travel funds from IBA
Clinical Report for Wanjie Proton Therapy Center. Li Jiamin, MD Wanjie Proton Therapy Center
Clinical Report for Wanjie Proton Therapy Center Li Jiamin, MD Wanjie Proton Therapy Center General Information Wanjie Proton Therapy Center was founded in June 2001 The first patient was treated in Dec.
Clinical Quality Assurance for Particle Therapy Plus ça même Plus
Clinical Quality Assurance for Particle Therapy Plus ça même Plus Thomas F. DeLaney, MD Medical Director Francis H. Burr Proton Center Massachusetts General Hospital Boston MA Quality Assurance Designed
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM GERM CELL TUMOURS CNS Site Group Germ Cell Tumours Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
Corporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: charged_particle_radiotherapy 3/12/96 5/2017 5/2018 5/2017 Description of Procedure or Service Charged-particle
Conflict of interest disclosure
Stereotactic Body Radiation Therapy (SBRT) I: Radiobiology and Clinical Experience Brian Kavanagh, M.D., MPH University of Colorado Eric Chang, M.D. UT MD Anderson Conflict of interest disclosure I have
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy
NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) BONE (Version , 03/28/18)
BONE (Version 2.2018, 03/28/18) NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) Radiation Therapy Specialized techniques such as intensity-modulated RT (IMRT); particle beam RT with protons, carbon ions,
When PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
Radiation Oncology MOC Study Guide
Radiation Oncology MOC Study Guide The following study guide is intended to give a general overview of the type of material that will be covered on the Radiation Oncology Maintenance of Certification (MOC)
DOES RADIOTHERAPY TECHNIQUE / DOSE / FRACTIONATION REALLY MATTER? YES
DOES RADIOTHERAPY TECHNIQUE / DOSE / FRACTIONATION REALLY MATTER? YES Marco Krengli Radiotherapy, Department of Translational Medicine, University of Piemonte Orientale A. Avogadro THE STANDARD OF CARE
The Role of Radiation Therapy in the Treatment of Brain Metastases. Matthew Cavey, M.D.
The Role of Radiation Therapy in the Treatment of Brain Metastases Matthew Cavey, M.D. Objectives Provide information about the prospective trials that are driving the treatment of patients with brain
Collection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Role of Radiosurgery in the Treatment of Gliomas Luis Souhami, MD Professor Department of Radiation
Surgical Management of Neuroendocrine Tumors of the Gut. Richard Hodin MD Professor of Surgery Massachusetts General Hospital Harvard Medical School
Surgical Management of Neuroendocrine Tumors of the Gut Richard Hodin MD Professor of Surgery Massachusetts General Hospital Harvard Medical School Sites of GI Carcinoid Tumors Small intestine 44% Rectum
Collection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology
TABLES. Table 1: Imaging. Congress of Neurological Surgeons Author (Year) Description of Study Classification Process / Evidence Class
TABLES Table 1: Imaging Kremer et al (2002) 2 Study Design: Prospective followed case series. Patient Population: Fifty adult patients with NFPA Study Description: Patients underwent MRI before surgery,
Clinical Trials of Proton Therapy for Breast Cancer. Andrew L. Chang, MD 張維安 Study Chair
Clinical Trials of Proton Therapy for Breast Cancer Andrew L. Chang, MD 張維安 Study Chair AndrewLChangMD@gmail.com Disclosure Proton Center Development Corporation Scripps San Diego Proton Therapy Center
A retrospective clinicopathological study of 37 patients with chordoma: a Danish national series
Sarcoma (1997) 1, 161-165 CARFAX ORIGINAL ARTICLE A retrospective clinicopathological study of 37 patients with chordoma: a Danish national series AKMAL SAFWAT, 10LE S. NIELSEN, ANNE G. JURIK, JOHNNY KELLER,
COLON AND RECTAL CANCER
No disclosures COLON AND RECTAL CANCER Mark Sun, MD Clinical Assistant Professor of Surgery University of Minnesota Colon and Rectal Cancer Statistics Overall Incidence 2016 134,490 new cases 8.0% of all
Primary Bone Tumors: Spine Surgery Live -Video Techniques Mobile Spine
Primary Bone Tumors: Spine Surgery Live -Video Techniques Mobile Spine Christopher Ames MD Professor of Neurosurgery and Orthopedic Surgery Director of Spine Tumor And Deformity Surgery UCSF Department
Ablative Radiation Therapy For Inoperable Cholangiocarcinoma. Christopher H. Crane, M.D. Program Director, GI Section Department of Radiation Oncology
Ablative Radiation Therapy For Inoperable Cholangiocarcinoma Christopher H. Crane, M.D. Program Director, GI Section Department of Radiation Oncology Facts about radiation treatment High doses (2x the
COLON AND RECTAL CANCER
COLON AND RECTAL CANCER Mark Sun, MD Clinical Associate Professor of Surgery University of Minnesota No disclosures Objectives 1) Understand the epidemiology, management, and prognosis of colon and rectal
Treatment results of proton beam therapy with chemo-radiotherapy for stage I-III esophageal cancer
Treatment results of proton beam therapy with chemo-radiotherapy for stage I-III esophageal cancer Nobukazu Fuwa 1, Akinori Takada 2 and Takahiro Kato 3 1;Departments of Radiology, Hyogo Ion Beam Medical
Particle Radiation Therapy: CurrentStatus Indications -Results
Particle Radiation Therapy: CurrentStatus Indications -Results Eugen B. Hug Center for Proton Therapy Paul Scherrer Institute and University of Zürich Switzerland Particle Radiation Therapy: Selection
Present status and future of Proton beam therapy
Present status and future of Proton beam therapy Description At present, the types of proven treatment for cancer are surgery, radiotherapy, and chemotherapy. Depending on the characteristics of cancer
Specification of Tumor Dose. Prescription dose. Purpose
Specification of Tumor Dose George Starkschall, Ph.D. Department of Radiation Physics U.T. M.D. Anderson Cancer Center Prescription dose What do we mean by a dose prescription of 63 Gy? Isocenter dose
A Comparison of IMRT and VMAT Technique for the Treatment of Rectal Cancer
A Comparison of IMRT and VMAT Technique for the Treatment of Rectal Cancer Tony Kin Ming Lam Radiation Planner Dr Patricia Lindsay, Radiation Physicist Dr John Kim, Radiation Oncologist Dr Kim Ann Ung,
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM LOW GRADE GLIOMAS CNS Site Group Low Grade Gliomas Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING
Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant CRT followed by Local Excision in ut2 Rectal Cancer
Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant CRT followed by Local Excision in ut2 Rectal Cancer Emily Chan, Qian Shi, Julio Garcia-Aguilar, Peter Cataldo, Jorge
Pre- Versus Post-operative Radiotherapy
Postoperative Radiation and Chemoradiation: Indications and Optimization of Practice Dislosures Clinical trial support from Genentech Inc. Sue S. Yom, MD, PhD Associate Professor UCSF Radiation Oncology
Image-guided, intensity-modulated radiation therapy (IG-IMRT) for skull base chordoma and chondrosarcoma: preliminary outcomes
Neuro-Oncology Neuro-Oncology 17(6), 889 894, 2015 doi:10.1093/neuonc/nou347 Advance Access date 27 December 2014 Image-guided, intensity-modulated radiation therapy (IG-IMRT) for skull base chordoma and
Effectiveness and Safety of Spot Scanning Proton Radiation Therapy for Skull Base Tumors: First Long Term Report of the PSI Experience
Effectiveness and Safety of Spot Scanning Proton Radiation Therapy for Skull Base Tumors: First Long Term Report of the PSI Experience Carmen Ares, Antony J Lomax, Eugen B Hug, Alessandra Bolsi, Beate
Advanced Pelvic Malignancy: Defining Resectability Be Aggressive. Lloyd A. Mack September 19, 2015
Advanced Pelvic Malignancy: Defining Resectability Be Aggressive Lloyd A. Mack September 19, 2015 CONFLICT OF INTEREST DECLARATION I have no conflicts of interest Advanced Pelvic Malignancies Locally Advanced
Intraoperative Radiotherapy
Intraoperative Radiotherapy Policy Number: 8.01.08 Last Review: 10/2018 Origination: 10/1988 Next Review: 10/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for radiation
Structured Follow-Up after Colorectal Cancer Resection: Overrated. R. Taylor Ripley University of Colorado Grand Rounds April 23, 2007
Structured Follow-Up after Colorectal Cancer Resection: Overrated R. Taylor Ripley University of Colorado Grand Rounds April 23, 2007 Guidelines for Colonoscopy Production: Surveillance US Multi-Society
Role of protons, heavy ions and BNCT in brain tumors
Role of protons, heavy ions and BNCT in brain tumors Prof G K Rath Head, NCI (AIIMS-2) Chief, Dr. BRA IRCH, Professor Radiation Oncology All India Institute of Medical Sciences, New Delhi 1 Overview of
JAMES EWING, Endothelial origin. 14 yr Girl
JAMES EWING, 1921 Endothelial origin 14 yr Girl SPECTRUM OF ESFT NEURAL DIFFERENTIATION Least Well EWING S SARCOMA ATYPICAL EWING S SARCOMA PNET Peripheral Neuroepithelioma ASKIN TUMOR (thoraco-pulmonary)
Case Conference: Post-Mastectomy Radiotherapy
Case Conference: Post-Mastectomy Radiotherapy Outline - Case Intro Guidelines Studies - Case Conclusion Summary Outline Case Intro to PMRT Guidelines Studies Case conclusion Summary Outline - Case Intro
AMERICAN BRAIN TUMOR ASSOCIATION. Proton Therapy
AMERICAN BRAIN TUMOR ASSOCIATION Proton Therapy ACKNOWLEDGEMENTS ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit
11/28/2018. Proton Therapy for Liver Cancer: Who, Why, and How. Disclosures. Michael Chuong, MD. None
Proton Therapy for Liver Cancer: Who, Why, and How Michael Chuong, MD Disclosures None 1 Rationale for proton therapy Hepatic toxicity Biliary toxicity GI toxicity Potentially significant benefit especially
Radiation Technology, Hyogo Ion Beam Medical Center, Tatsuno, Hyogo, JAPAN
Analysis of Visual Loss Due to Radiation- Induced Optic Neuropathy After Particle Therapy for Head and Neck and Skull Base Tumors Adjacent to Optic Nerves Y. Demizu 1, M. Murakami 1, D. Miyawaki 1, Y.
Early Rectal Cancer Surgical options Organ Preservation? Chinna Reddy Colorectal Surgeon Western General, Edinburgh
Early Rectal Cancer Surgical options Organ Preservation? Chinna Reddy Colorectal Surgeon Western General, Edinburgh What is Early rectal cancer? pt1t2n0m0 Predictors for LN involvement Size Depth Intramural
-Proton Beam Therapy in Paediatric Radiation Oncology -
-Proton Beam Therapy in Paediatric Radiation Oncology - Beate Timmermann, M.D. West German Proton Therapy Centre Essen Germany Preview Survival Toxicity Why protons? (theoretically) Experiences so far
Advances in external beam radiotherapy
International Conference on Modern Radiotherapy: Advances and Challenges in Radiation Protection of Patients Advances in external beam radiotherapy New techniques, new benefits and new risks Michael Brada
Proton Therapy for Ependymoma and Craniopharyngioma at the University of Florida: Lessons Learned About Efficacy and Toxicity
Proton Therapy for Ependymoma and Craniopharyngioma at the University of Florida: Lessons Learned About Efficacy and Toxicity Danny Indelicato, MD Mendenhall Chair of Pediatric Radiotherapy University
Treatment strategy of metastatic rectal cancer
35.Schweizerische Koloproktologie-Tagung Treatment strategy of metastatic rectal cancer Gilles Mentha University hospital of Geneva Bern, January 18th, 2014 Colorectal cancer is the third most frequent
Radiotherapy Considerations in Extremity Sarcoma
Radiotherapy Considerations in Extremity Sarcoma Peter Chung Department of Radiation Oncology Princess Margaret Hospital University of Toronto Role of RT in STS Local tumour eradication while allowing
Radiation Therapy 2013 The Role of Protons. Bob Gaston, D.O.
Radiation Therapy 2013 The Role of Protons Bob Gaston, D.O. Disclosures Oklahoma ProCure Treatment Center Radiation Medicine Associates Goal of Radiation Therapy Increase the Therapeutic Ratio Therapeutic
Case Report Carbon Ion Beam Radiotherapy for Sinonasal Malignant Tumors Invading Skull Base
Case Reports in Otolaryngology, Article ID 241856, 4 pages http://dx.doi.org/10.1155/2014/241856 Case Report Carbon Ion Beam Radiotherapy for Sinonasal Malignant Tumors Invading Skull Base Nobuo Ohta,
11/3/2016. Outcomes Watching It Grow. What will we discuss? GATRA Annual Conference 2016 Lisa Connor, CTR
Outcomes Watching It Grow GATRA Annual Conference 2016 Lisa Connor, CTR The abstract begins after case finding The abstract is in progress The abstract is complete The abstract is revisited and nurtured